Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | NAMPT | P43490 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21659378 | 0.86 | MAPT (0.58) | MAPTLMNAALDH1A1GPR119SMN1; SMN2 | |
| SCHEMBL22776398 | 0.86 | MAPT (0.58) | MAPTLMNAALDH1A1GPR119SMN1; SMN2 | |
| SCHEMBL23868398 | 0.86 | MAPT (0.58) | MAPTLMNAALDH1A1GPR119SMN1; SMN2 | |
| SCHEMBL21659187 | 0.85 | MAPT (0.60) | MAPTLMNAALDH1A1GPR119SMN1; SMN2 | |
| SCHEMBL21659329 | 0.85 | MAPT (0.57) | MAPTLMNAALDH1A1GPR119SMN1; SMN2 | |
| SCHEMBL3575001 | 0.85 | MAPT (0.57) | MAPTLMNAALDH1A1GPR119SMN1; SMN2 | |
| SCHEMBL3116747 | 0.85 | MAPT (0.57) | MAPTLMNAALDH1A1GPR119SMN1; SMN2 | |
| SCHEMBL24091548 | 0.85 | EGLN2 (0.51) | MAPTLMNAALDH1A1GPR119 | |
| SCHEMBL20305774 | 0.84 | MAPT (0.56) | MAPTLMNAALDH1A1GPR119SMN1; SMN2 | |
| SCHEMBL24378197 | 0.84 | MAPT (0.61) | MAPTLMNAALDH1A1GPR119SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110742893-B | Methods of treating cancer with A2A receptor antagonists | 百济神州(北京)生物科技有限公司 | 2024-04-05 | — | — | CN | disclosed |
| US-20210300936-A1 | PYRAZOLOTRIAZOLOPYRIMIDINE DERIVATIVES AS A2A RECEPTOR ANTAGONIST | BEONE MEDICINES I GMBH (CH) | 2021-09-30 | — | — | US | disclosed |
| US-20210300936-A1 | PYRAZOLOTRIAZOLOPYRIMIDINE DERIVATIVES AS A2A RECEPTOR ANTAGONIST | BEONE MEDICINES I GMBH (CH) | 2021-09-30 | — | — | US | disclosed |
| CN-112469722-A | Pyrazolo-triazolopyrimidine derivatives as A2A receptor antagonists | 百济神州有限公司 | 2021-03-09 | — | — | CN | disclosed |
| CN-110742893-A | Methods of treating cancer with A2A receptor antagonists | 百济神州(北京)生物科技有限公司 | 2020-02-04 | — | — | CN | disclosed |
| WO-2020020097-A1 | PYRAZOLOTRIAZOLOPYRIMIDINE DERIVATIVES AS A2A RECEPTOR ANTAGONIST | BEIGENE, LTD. (KY) | 2020-01-30 | — | — | WO | disclosed |
| EP-1396487-B1 | PHENYLPYRIDINE CARBONYL PIPERAZINE DERIVATIVE | ASTELLAS PHARMA INC (JP) | 2008-12-10 | — | — | EP | disclosed |
| US-7196080-B2 | Respiratory system disordeers; chronic obstructive pulminary disease | ASTELLAS PHARMA INC. (JP) | 2007-03-27 | — | — | US | disclosed |
| CN-1300114-C | Phenylpyridine formyl piperazine derivatives | YAMANOUCHI PHARMA CO LTD (JP) | 2007-02-14 | — | — | CN | disclosed |
| US-20040192701-A1 | Phenlypyridine carbonyl piperazine derivative | ASTELLAS PHARMA INC. (JP) | 2004-09-30 | — | — | US | disclosed |
| CN-1516691-A | Phenylpyridine carbonyl piperazine derivative | ֮����ҩ��ʽ���� | 2004-07-28 | — | — | CN | disclosed |
| EP-1396487-A1 | PHENYLPYRIDINE CARBONYL PIPERAZINE DERIVATIVE | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2004-03-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300936-A1 | PYRAZOLOTRIAZOLOPYRIMIDINE DERIVATIVES AS A2A RECEPTOR ANTAGONIST | ADORA2A, ADORA3, ADORA2B | MAPT 4383/4885LMNA 4609/4885ALDH1A1 1114/4885 |
| US-20040192701-A1 | Phenlypyridine carbonyl piperazine derivative | PDE5A, PDE4A, PDE3B | MAPT 4798/4885LMNA 3464/4885ALDH1A1 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.